Topic Archives: Internap (INAP)

Dan Miller works for GAMCO investors and the Gabelli funds, he manages 35 industry analysts. His talk is called “Investing with Conviction”, and he’s working with the Gabelli concept of “private market value” — they call it “PMV with a Catalyst” and he published a quarterly list of the “Focus Five” — the five most […]

Comments

  • Avatar

    I've often wondered how companies that develop something that eliminates disease, such as this, will make money. The OUT...

  • Travis Johnson, Stock Gumshoe

    Thanks, I didn’t run across the Boston presentation....

  • Avatar

    SGMO has lost nearly half it's value since late Aug., 2018! What has the market done since then??? NEXT!!!...

  • Avatar

    If SGMO had anything worth pursuing they would have been bought out by now. Wait until they get approval and start makin...

  • Avatar

    SGMO is down 34% at 1:30 EST. Down more at 11:30, but seem to have risen a little....

  • Avatar

    It is Sangamo Therapeutics ( SGMO )....

  • Avatar

    The ONLY gene editing stock to own is SGMO. No off targets unlike the rest. 7 readouts this year. Imo, will cure HIV ...

  • Avatar

    Does anyone own Sangamo Therapeutics. (SGMO) I should call myself the "Greenhorn" because I know virtually nothing about...

  • Avatar

    Thanks for putting everything into perspective. I read about "exciting new developments" every day, and it is impossibl...

  • Avatar

    SGMO down 20% today looks like things didn't go so well: https://www.marketwatch.com/story/sangamo-stock-drops-13-pre...

  • Avatar

    Good results but shares drop 20% good spot from Travis, on the opportunity to buy as it happens that would seem to be t...

  • Travis Johnson, Stock Gumshoe

    Right, that's the dream of future possibility... but the first trial data is for a very small disease. Not unusual, jus...

  • Avatar

    Hi All , Sangamo are holding a conference call today just after the presentation in Greece, The call will follow the ...

  • Avatar

    https://www.fool.com/investing/2018/09/03/why-sangamo-therapeutics-shot-337-higher-in-august.aspx...

  • Avatar

    As usual - you got it right...:) Confirming its SGMO, recommended up to 20.00 or the SGMO Sept 2018 17 calls for 3 or ...

  • Avatar

    I own a few shares of SGMO, along with CRSP, EDIT, and NLT, and 16 other micro cap Biogen stocks, and I feel that this i...

  • Avatar

    NOVUS reported the following top five 2015 Q1 hedge fund stock-pickers in the Healthcare sector: RA Cap Management; BB...

  • omcdac1

    Patents by Assignee Sangamo Biosciences, Inc. http://patents.justia.com/assignee/sangamo-biosciences-inc...

  • AC/DC

    Long post alert. Mostly for Doc KSS. I remember Sangamo Biosciences ($SGMO) being discussed earlier w.r.t. BLUE. I was ...

  • SoGiAm

    Leo S - RE: Biotechnology Threads Focus- My point is Leo S Look at the BioTech equities that increased Thursday and Frid...

  • Avatar

    The following info about RA Capital's holdings, as at end of 2013 may be of interest to some of you: 37 Positions as of...

  • Avatar

    Hi Booya (maybe you are Cramer) re your reply on March 5th to the original post #10 dated 1/8/2014 on Sangamo Bioscience...

  • Avatar

    SGMO Trading at $23.75ish off a $19.61 close on the news below. Sangamo BioSciences announced the publication in t...

  • Avatar

    I own shares of Sangamo Biosciences (SGMO). Sangamo is focused on the research and commercial development of engineered ...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info